Vasson M-P, Talvas J, Perche O, Dillies A-F, Bachmann P, Pezet D, Achim A-C, Pommier P, Racadot S, Weber A, Ramdani M, Kwiatkowski F, Bouteloup C
CHU Clermont-Ferrand, Centre Jean Perrin, Unité de Nutrition, CLARA, F-63000 Clermont-Ferrand, France; Clermont Université, Université d'Auvergne, UMR 1019, Unité de Nutrition Humaine, CRNH-Auvergne, BP 10448, F-63000 Clermont-Ferrand, France.
Clermont Université, Université d'Auvergne, UMR 1019, Unité de Nutrition Humaine, CRNH-Auvergne, BP 10448, F-63000 Clermont-Ferrand, France.
Clin Nutr. 2014 Apr;33(2):204-10. doi: 10.1016/j.clnu.2013.06.008. Epub 2013 Jun 20.
BACKGROUND & AIMS: Malnutrition is frequent in head and neck (HN) and esophageal cancer patients and aggravated by radiochemotherapy (RCT), increasing morbi-mortality and treatment toxicity. Our goal was to investigate the effect of immunonutrition consisting of an arginine, omega-3 fatty acid, nucleotides-enriched diet on nutritional status, and functional capacity in HN or esophageal cancer patients undergoing RCT.
37 patients were randomized in a double-blind clinical trial. 5 days before and until the end of RCT (5-7 weeks), they received either an Immunomodulating Enteral Nutrition (IEN) or an isonitrogenous, isoenergetic Standard Enteral Nutrition (SEN). Anthropometrical parameters, nutritional risk index (NRI), serum albumin, plasma antioxidant capacity, and functional capacity were recorded between the beginning and the end of RCT.
A significant gain in total body weight (+2.1 ± 3.1 kg) was observed in IEN patients. Albuminemia and NRI were improved concomitantly in IEN malnourished patients. Plasma antioxidant capacity was improved (+100 ± 13 μM EqTrolox) in IEN patients. Functional capacity measured by WHO Performance Status and Karnofsky index was maintained in IEN patients but significantly reduced in SEN patients.
These preliminary data show that immunonutrition could improve the nutritional status together with functional capacity in HN and esophageal cancer patients undergoing RCT.
This clinical trial promoted by the University Hospital Center of Clermont-Ferrand has been registered at ClinicalTrial.gov website under the following reference: NCT00333099.
营养不良在头颈部(HN)和食管癌患者中很常见,并且会因放化疗(RCT)而加重,从而增加病亡率和治疗毒性。我们的目标是研究由富含精氨酸、ω-3脂肪酸和核苷酸的饮食组成的免疫营养对接受RCT的HN或食管癌患者营养状况和功能能力的影响。
37例患者被随机纳入一项双盲临床试验。在RCT开始前5天直至结束(5 - 7周),他们分别接受免疫调节肠内营养(IEN)或等氮、等能量的标准肠内营养(SEN)。在RCT开始和结束时记录人体测量参数、营养风险指数(NRI)、血清白蛋白、血浆抗氧化能力和功能能力。
IEN组患者总体重显著增加(+2.1±3.1 kg)。IEN组营养不良患者的白蛋白血症和NRI同时得到改善。IEN组患者血浆抗氧化能力提高(+100±13 μM Eq Trolox)。通过世界卫生组织表现状态和卡诺夫斯基指数测量的功能能力在IEN组患者中得以维持,但在SEN组患者中显著降低。
这些初步数据表明,免疫营养可改善接受RCT的HN和食管癌患者的营养状况及功能能力。
这项由克莱蒙费朗大学医院中心发起的临床试验已在ClinicalTrial.gov网站注册,注册号如下:NCT00333099。